Grant Number: 5R01DA011792-08
Project Title: Anxiolytic Effects and Abuse of BZ Receptor
Ligands
PI Information: CHIEF JAMES K. ROWLETT,
james_rowlett@hms.harvard.edu
Abstract: DESCRIPTION (provided by applicant):
Benzodiazepines (BZs) are prescribed widely as anxiolytics, hypnotics,
muscle relaxants, and anticonvulsants. Although BZs are considered to be
among the safest prescription drugs in modem medicine, their utility is
constrained by a number of side effects, including unwanted sedation,
impaired motor performance, and the liability for abuse and dependence.
The overall goal of this application is to investigate the contribution
of different GABAA receptor subtypes to the anxiolytic, abuse-related,
and sedative/motoric effects of BZ ligands in relevant nonhuman primate
models. Ligands that exhibit preferential binding or preferential
agonist activity at GABAA receptors containing different (x subunits
will be used to investigate the potential contribution of these receptor
subtypes to various behavioral effects of BZs. Behavior predictive of
anxiolytic activity will be studied in rhesus monkeys using a conflict
procedure in which food-maintained behavior is concurrently suppressed
by response-produced presentations of an aversive stimulus. Abuse
potential will be studied using a progressive-ratio schedule of IV drug
self-administration. Sedation and motor performance will be examined
using direct observation techniques and an automated procedure for
assessment of motor coordination. Quantitative pharmacological analysis
will be used in conjunction with drug interaction studies to investigate
the potential contribution of GABAA receptor subtypes across these
different behaviors. The results of these studies will provide relevant
information for understanding the role of different GABAA receptor
subtypes in the anxiolytic, abuse-related, and sedative/motoric effects
of BZ ligands. The results also should facilitate identification of
effective anxiolytic compounds with decreased side effects and reduced
abuse potential.
Thesaurus Terms:
GABA receptor, benzodiazepine, benzodiazepine receptor, drug abuse,
ligand, psychopharmacology, tranquilizer
dosage, drug administration rate /duration, drug adverse effect, drug
interaction, pharmacokinetics, psychological reinforcement, receptor
expression, self medication, stimulant /agonist, triazolam
Macaca mulatta, behavior test
Institution: HARVARD UNIVERSITY (MEDICAL SCHOOL)
MEDICAL SCHOOL CAMPUS
BOSTON, MA 02115
Fiscal Year: 2006
Department: PSYCHIATRY
Project Start: 15-JUN-1998
Project End: 31-MAY-2009
ICD: NATIONAL INSTITUTE ON DRUG ABUSE
IRG: BBBP
Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 1, 2005; DOI: 10.1124/jpet.104.081612
Contribution of GABAA Receptor Subtypes to the
Anxiolytic-Like, Motor, and Discriminative Stimulus Effects of
Benzodiazepines: Studies with the Functionally Selective Ligand SL651498
[6-Fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one]
Stephanie C. Licata, Donna M. Platt, James M. Cook, P. V. V. Srirama
Sarma, Guy Griebel, and James K. Rowlett
Harvard Medical School, New England Primate Research Center,
Southborough, Massachusetts (S.C.L., D.M.P., J.K.R.); University of
Wisconsin-Milwaukee, Milwaukee, Wisconsin (J.M.C., P.V.V.S.S.); and
Central Nervous System Research Department, Sanofi-Aventis, Bagneux,
France (G.G.)
Received December 3, 2004; accepted January 31, 2005.
Subjects.
Four adult rhesus monkeys (Macaca mulatta), two male and two female,
were studied in the conflict study. Six adult male squirrel monkeys (Saimiri
sciureus) were used for the observational study, and four adult male
squirrel monkeys were used in the drug discrimination study. Monkeys
used in the conflict and discrimination studies were maintained at 90 to
95% of their free-feeding weight. Monkeys used in the observational
study were maintained under free-feeding conditions. All monkeys were
housed individually and maintained under a 12-h light/dark cycle in a
temperature- and humidity-controlled room. All procedures were conducted
with the approval and under the supervision of the Harvard University
Institutional Animal Care and Use Committees. Animals in this study were
maintained in accordance with the guidelines of the Committee on Animals
of the Harvard Medical School and the "Guide for Care and Use of
Laboratory Animals" National Research Council, Department of Health,
Education and Welfare Publication No. (NIH 85-23), revised 1996.
Monkeys in the conflict and discrimination studies were prepared with
chronic indwelling venous catheters using the general surgical
procedures described by Carey and Spealman (1998 ). Under isoflurane
anesthesia and aseptic conditions, one end of a polyvinyl chloride
catheter (rhesus monkey = i.d., 0.64 mm; o.d., 1.35 mm; squirrel monkey
= i.d., 0.38 mm; o.d., 0.76 mm) was passed to the level of the right
atrium by way of a brachial, femoral, or jugular vein. The distal end of
the catheter was passed subcutaneously and exited in the mid-scapular
region. Rhesus monkey catheters were flushed daily with heparinized
saline (150–200 U/ml), whereas squirrel monkey catheters were flushed
daily with saline that did not contain heparin. All catheters were
sealed with stainless steel obturators when not in use. Monkeys wore
custom-made nylon mesh jackets (Lomir Biomedical, Toronto, ON, Canada)
at all times to protect the catheter.
Conflict Study.
Rhesus monkeys were trained to sit in a custom-designed restraint chair
(Crist Instruments, Hagerstown, MD) located in a sound-attenuating
chamber. A response lever, stimulus lights (Med Associates, Georgia,
VT), and a receptacle into which food pellets (1 g of
marshmallow-flavored pellets; BioServ, French-town, NJ) were delivered
were positioned in front of the monkey. Monkeys were trained on a
multiple schedule of food reinforcement consisting of two components: 1)
a schedule of food pellet delivery, and 2) a schedule of food pellet
delivery plus a schedule of foot shock delivery (0.25-s duration, 1–3 mA
depending on the individual monkey). Four components were available in a
session, separated by 10-min timeout periods in which responding had no
programmed consequences. Responding was maintained in each component
under an 18 response, fixed-ratio (FR) schedule of food pellet delivery.
Each component consisted of the schedule of food pellet delivery
signaled by red stimulus lights, followed immediately by the same
schedule of food delivery combined with a 20 response FR schedule of
foot shock delivery signaled by green stimulus lights. Each response
requirement was followed by a 10-s timeout. Drugs were administered
during the 5th min of the 10-min timeout that preceded each component.
Training sessions were conducted 5 days per week until performance
(measured as rates of responding, see below) in both "food only" and
"food + shock" components was stable (i.e., no upward or downward trends
for 3 consecutive days). In addition, if rates of responding in a
component during a training session varied by more than 20% of the
corresponding response rates in the previous training session,
additional training sessions were conducted until responding was again
stable. Once training criteria were met, test sessions were conducted
once or twice a week, separated by at least 2 days. Dose-response
functions were determined for test drugs using a cumulative dosing
procedure similar to the one described by Rowlett et al. (2001 ).
Four-point cumulative dose-response functions were determined within a
single test session as a result of incremental increases in drug
(one-half log units) administered at the 5th min of the 10-min timeout
period. Dose-response functions were determined for SL651498 (0.1–3
mg/kg), the classical nonselective BZ agonist chlordiazepoxide (1–30
mg/kg), as well as triazolam (0.001–0.03 mg/kg).
The number of responses in a component, minus responding during pellet
delivery and the 10-s timeouts, was divided by the total component time
minus the 10-s timeouts to obtain rates of responding (responses per
second). Data for multiple determinations were averaged for an
individual monkey, and then these response rates were averaged across
monkeys (N = 4, unless otherwise noted). The effects of the individual
doses of drug were compared with the control rates of responding using
Dunnett's test comparing the average response rate engendered by each
dose to the average response rate after vehicle administration ( level =
p < 0.05).
Observation Study. The observable behavioral effects of BZ ligands were
assessed in squirrel monkeys according to the procedures described by
Platt et al. (2002 ). Each monkey was habituated to a ventilated,
transparent Plexiglas arena (114 cm x 122 cm x 213 cm). This observation
arena was equipped with perches, suspended plastic chains, and a wood
chip foraging substrate to allow the monkeys to express a range of
species-typical behaviors. A video camera was positioned 1 m in front of
the chamber and operated throughout the 30-min session.
Drug testing was conducted once or twice per week with control sessions
preceded by saline injections on intervening days. Doses of SL651498
(0.3–10 mg/kg i.m., administered 10 min prior to the start of the
session) or chlordiazepoxide (3.0–56 mg/kg i.m., administered 30 min
prior to start of the session) were administered on separate test days.
Trained observers, unaware of the drug being studied, scored the
videotapes by recording the presence or absence of each of eight
behaviors (Table 1) at 15-s intervals during three 5-min observation
periods across the session (0–5, 12–17, and 24–29 min). For each
subject, frequency scores (defined as the total number of 15-s intervals
in which a particular behavior was observed; maximum score = 20) for
each behavior were averaged across the three observation periods of a
session because no reliable differences in scores were identified by
separated repeated measures analysis of variance. Scores were then
averaged across subjects to obtain group means. To determine statistical
reliability of treatment effects on each behavior, the effect of dose
was determined for each drug by separate repeated measures analyses of
variance. Treatment effects were assessed further using Bonferroni t
tests, in which the effects of different doses of each drug were
compared with vehicle.
Muscle relaxation and ataxia were measured in the same animals during
the 6th, 18th, and 30th min of each 30-min observation session. The
monkeys were removed briefly from the observation arena by a trained
handler and evaluated for degree of muscle relaxation, which was defined
as decreased resistance to extension of a hind limb. A score of 0
indicated a normal resistance to extension, a score of (–1) indicated a
decreased resistance to extension, and a score of (–2) indicated no
resistance to extension (i.e., the monkey was flaccid and completely
relaxed). Ataxia was defined as the inability to balance on the 1-cm
diameter stainless steel transport pole held in the horizontal plane. A
score of 0 indicated that the monkey was able to balance normally on the
pole, a score of (+1) indicated that the monkey was able to hold onto
the pole but unable to maintain balance (e.g., suspended by limbs below
pole), and a score of (+2) indicated that the monkey could neither
balance on nor hold on to the pole.
In an additional study, SL651498 (10 mg/kg i.m.), chlordiazepoxide (56
mg/kg i.m.), or triazolam (0.1 mg/kg i.m., administered 30 min prior to
the start of the session) were evaluated alone and combined with the
1GABAA-preferring antagonist -carboline-3-carboxylate-t-butyl ester ( -CCT)
(Platt et al., 2002 ; 3.0 mg/kg i.m., administered 10 min prior to the
start of the session). Monkeys were evaluated for muscle relaxation and
ataxia.
Drug Discrimination Study.
Squirrel monkeys were trained to discriminate the conventional BZ
agonist triazolam from saline under an FR 10 schedule of food delivery
using the procedure described by Lelas et al. (2001 , 2002 ). The
monkeys sat in a restraint chair located in a sound-attenuating chamber
(Med Associates). In front of the monkey, response levers and stimulus
lights were available as well as a receptacle into which food pellets
(190 mg of sucrose pellets; BioServ) were delivered. Training sessions
consisted of one to four components. A 10-min timeout period preceded
each FR component, and either saline or triazolam (0.03 mg/kg) was
administered intravenously at the 5th min. Each FR component, during
which the stimulus lights were illuminated and the FR 10 schedule of
food delivery was in effect, lasted 5 min or until 10 pellets were
delivered, whichever occurred first. Ten consecutive responses on the
correct lever resulted in food delivery and extinguished the stimulus
lights for a 10-s timeout period. Responses on the incorrect lever did
not result in pellet delivery and reset the response requirement on the
correct lever.
Drug testing sessions were conducted once or twice per week with
training sessions scheduled on intervening days. Test sessions were
conducted if 80% or more of the total responses occurred on the lever
designated correct for that component for at least four of the five
preceding training sessions. Test sessions consisted of i.v. injections
of saline, triazolam (0.003–0.1 mg/kg), or SL651498 (0.1–1 mg/kg).
Overlapping cumulative dose-response functions were administered on
different test sessions until at least one dose of drug produced 80%
drug-lever responding, decreased response rates to 25% of control, or
resulted in two or more animals not completing a response requirement.
Antagonism studies also were conducted in which selected doses of -CCT
(0.3 and 1.0 mg/kg i.v.) were studied in combination with SL651498. -CCT
and its vehicle control were administered i.v. in the first component
similar to previous studies (Lelas et al., 2002 ). |